<DOC>
	<DOC>NCT00613314</DOC>
	<brief_summary>To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.</brief_summary>
	<brief_title>Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Age &gt; 45 years Increased waist circumference (&gt;88.9cm [&gt;35in] men, &gt;78.7cm [&gt;31in] for women) Elevated triglycerides (&gt;150mg/dl) Low HDL cholesterol (&lt;40mg/dl in men, &lt;50mg/dl in women) Hypertension (&gt;130/&gt;85mmHG) Impaired fasting glucose (&gt;110mg/dl) (8) Hypertensive patient assessed to benefit from telmisartan based treatment Hypersensitivity to telmisartan, hydrochlorothiazide (HCTZ) and its excipients &lt;3 months myocardial infarction (MI), stroke or severe heart failure</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>